The Effective Use of Anti-obesity Medications.
Anti-obesity medications
Combination therapy
GLP-1 receptor agonists
Obesity pharmacotherapy
Off-label prescribing
Treatment of obesity
Journal
Gastroenterology clinics of North America
ISSN: 1558-1942
Titre abrégé: Gastroenterol Clin North Am
Pays: United States
ID NLM: 8706257
Informations de publication
Date de publication:
12 2023
12 2023
Historique:
medline:
6
11
2023
pubmed:
3
11
2023
entrez:
2
11
2023
Statut:
ppublish
Résumé
Obesity is a heterogeneous disease and there is wide patient-to-patient variability in response to all anti-obesity treatments including lifestyle modifications, anti-obesity medications (AOMs), devices, and bariatric surgery. To effectively treat obesity, practitioners must be knowledgeable about all of these treatment modalities including on-label and off-label AOMs. Care should be individualized to the patient taking into consideration their unique challenges with weight loss, their goals, the presence of comorbidities, medication contraindications, and drug-drug interactions. There is currently no way to know which AOM will be most effective for a patient without trial and error; therefore, prescribe AOMs in sequence and consider combination therapy for optimal results. This article reviews the efficacy, safety, prescribing information, and other considerations for all of the currently available AOMs.
Identifiants
pubmed: 37919019
pii: S0889-8553(23)00081-X
doi: 10.1016/j.gtc.2023.08.003
pii:
doi:
Substances chimiques
Anti-Obesity Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
661-680Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure S.H. Schmitz reports no disclosures. L.J. Aronne reports receiving consulting fees from/and serving on advisory boards for Allurion, Altimmune, Atria, Gelesis, Jamieson Wellness, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Novo Nordisk, Pfizer, Optum, Eli Lilly, Senda Biosciences and Versanis; receiving research funding from Allurion, AstraZeneca, United Kingdom, Gelesis, Janssen Pharmaceuticals, United States, Novo Nordisk and Eli Lilly; having equity interests in Allurion, ERX Pharmaceuticals, Gelesis, Intellihealth, Jamieson Wellness and Myos Corp; and serving on a board of directors for ERX Pharmaceuticals, Intellihealth and Jamieson Wellness.